Overview

A Study of MK-1088 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors (MK-1088-002)

Status:
Not yet recruiting

Trial end date:
2025-09-17

Target enrollment:

Participant gender:

Summary

The study will evaluate the safety, tolerability, and pharmacokinetics (PK) of MK-1088 in monotherapy and in combination with pembrolizumab in participants with advanced solid tumors who have not responded to conventional therapy. The effect of MK-1088 on tumor size will also be examined.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Merck Sharp & Dohme LLC

Treatments:

Pembrolizumab